Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spain And Portugal Team Up To Buy Medicines

Executive Summary

Spain and Portugal have announced plans to work more closely together to buy new medicines and are now planning a pilot.

You may also be interested in...



More European Countries Agree To Swap Pricing Info And Negotiate Prices

Another alliance among EU countries to tackle high medicines prices is gathering pace. Eight countries are to soon start swapping pricing information and have agreed to join forces to negotiate more affordable prices.

Denmark and Norway Consider Joint Purchasing Pilot For Lower Prices

Norway and Denmark are exploring the idea a pilot project that would see them jointly purchase medicines.

Where Europe’s ‘BeNeLuxA’ Joint Pricing Pilot May Have Gone Wrong

A more innovative approach to pricing and reimbursement arrangements is needed in the pilot BeNeLuxA joint pricing negotiations, says Eurordis head Yann Le Cam. The Netherlands and Belgium are expected to re-start the negotiations soon after a “time-out” period.

Topics

UsernamePublicRestriction

Register

PS121087

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel